Leafcann granted three medical cannabis licences
Published 16-AUG-2019 12:37 P.M.
|
3 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
The unlisted LeafCann Group Pty Ltd announced this week that it has received its Australian Cannabis Research and Medicinal Cannabis (Cultivation) licences from the Australian Office of Drug Control.
LeafCann is attempting to advance the re-introduction of plant-based extracts in medicine and nutrition through conducting and supporting product and industry research and development, clinical trials, commercial production and GMP manufacturing.
It is, in fact, building a robust and agile Medicinal Cannabis supply chain, forging export agreements and working towards ensuring patients have access to precision cannabis medicines made from the highest quality ingredients at affordable prices.
In May, the company was granted a licence to Manufacture Medicinal Cannabis by the Australian Office of Drug Control.
“After several years of Company development, I am delighted that Leafcann can now begin in earnest to execute our business plan towards delivering medicinal cannabis products to the many patients whose conditions are not treated effectively by existing pharmaceuticals, and whose quality of life could be substantially improved," said LeafCann Group CEO, Ms. Elisabetta Faenza.
"The LeafCann team’s vision is to deliver a world class outcome for the medical market by leading the sector in the development of person-centred precision medicines under GMP (Good Manufacturing Practice) production. We look forward to continued engagement with regulators and licenced industry partners to provide effective, validated medicines to those that need it most,”
This week's announcement means that combined with its existing Manufacturing Licence, LeafCann now holds a complete set of licences and can fulfil its ambition of providing high quality medicines using its ‘seed to sale’ capabilities.
“This is such an exciting moment for the whole organisation,” said Faenza, “the next 12-18 months are going to be extremely exciting as we roll-out our detailed plans and turn these licences into a business that produces person-centred, precision medicines for Australian patients, creating exceptional value for our customers, staff and investors.”
Leafcann Group Chief Scientist, Dr Jaroslav Boublik added, “I’m very pleased that LeafCann Group now holds all three ODC cannabis licences, as this clears the way for execution of the plans we have been developing since the founding of the companies. We now look forward to making a significant contribution to the growth of a robust and vibrant medicinal cannabis industry in Australia, and providing patients with new, innovative medicines for a range of ailments.”
LeafCann Group Chairman, Mr Ilario Faenza added, “The granting of these additional Licences for our first integrated Australian facility, LeafCann Innovate, is a significant milestone for the company and will enable LeafCann to finalise the upgrade of the existing facility and commence operations.”
LeafCann will use its Adelaide-based facility to conduct its initial research, cultivation and manufacturing operations, expected to be fully operational by the beginning of 2021.
General Information Only
This material has been prepared by Jason Price. Jason Price is an authorised representative (AR 000296877) of 62 Consulting Pty Limited (ABN 88 664 809 303) (AFSL 548573) (62C), and a Director of S3 Consortium Pty Ltd (trading as StocksDigital).
This material is general advice only and is not an offer for the purchase or sale of any financial product or service. The material is not intended to provide you with personal financial or tax advice and does not take into account your personal objectives, financial situation or needs. Although we believe that the material is correct, no warranty of accuracy, reliability or completeness is given, except for liability under statute which cannot be excluded. Please note that past performance may not be indicative of future performance and that no guarantee of performance, the return of capital or a particular rate of return is given by 62C, Jason Price, StocksDigital, any of their related body corporates or any other person. To the maximum extent possible, 62C, Jason Price, StocksDigital, their related body corporates or any other person do not accept any liability for any statement in this material.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
